Christou Niki, Perraud Aurélie, Blondy Sabrina, Jauberteau Marie-Odile, Battu Serge, Mathonnet Muriel
Laboratoire EA 3842, Homéostasie cellulaire et Pathologies, Faculté de Médecine et de Pharmacie, Université de Limoges, 2 rue du Dr Marcland, 87025, Limoges Cedex, France.
Institut Fédératif de Recherche 145 GEIST « Génomique, Environnement, Immunité, Santé et Thérapeutiques », Université de Limoges, 2 rue du Dr Marcland, 87025, Limoges Cedex, France.
J Cancer Res Clin Oncol. 2017 Jul;143(7):1177-1190. doi: 10.1007/s00432-017-2382-x. Epub 2017 Mar 13.
Multiple studies have attempted to demonstrate the interest of the cell adhesion marker, E cadherin, as a diagnostic and prognosis marker in colorectal cancer (CRC). However, it was considered non specific.
Studies were carried out with CRC cell lines and patients' cohort operated for CRC. The expression of E cadherin was studied after 5 fluorouracil (5FU) treatment and correlated to CRC relapse, chemo-resistance and survival.
In CRC cell lines derived from high tumor stages, extracellular domain of E cadherin expression decreased after 5FU treatment whereas it increased in supernatants. Interestingly, only specific cleaved forms at 55 kDa of E cadherin were detected in supernatants. In CRC surgical patients, more importantly concerning extracellular E cadherin domain, a decreased expression was observed in tissues in function of CRC stages whereas an increased expression was found in sera. Moreover, there is an increasing trend of survival with weak serum E cadherin secretion, reinforcing the implication of this protein in CRC evolution.
The extracellular domain can be defined as a 5FU resistance marker and allow CRC monitoring.
多项研究试图证明细胞黏附标志物E-钙黏蛋白作为结直肠癌(CRC)诊断和预后标志物的价值。然而,它被认为是非特异性的。
对CRC细胞系以及接受CRC手术的患者队列进行研究。研究5-氟尿嘧啶(5FU)治疗后E-钙黏蛋白的表达,并将其与CRC复发、化疗耐药性和生存率相关联。
在源自高肿瘤分期的CRC细胞系中,5FU治疗后E-钙黏蛋白细胞外结构域的表达降低,而在上清液中其表达增加。有趣的是,在上清液中仅检测到55 kDa的E-钙黏蛋白特异性裂解形式。在接受CRC手术的患者中,更重要的是关于细胞外E-钙黏蛋白结构域,在组织中观察到其表达随CRC分期而降低,而在血清中其表达增加。此外,血清E-钙黏蛋白分泌较弱时生存率有上升趋势,这进一步证明了该蛋白在CRC进展中的作用。
细胞外结构域可被定义为5FU耐药标志物并用于监测CRC。